These collective data supported FDA accelerated approval (December 6, 2018; BLA 761034Orig1s014) for the four‐drug combination in PD‐L1‐positive (SP142 assay ≥ 1% TC/IC) metastatic nonsquamous NSCLC [56]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.